Serum albumin ≥ 3 was protective and associated with a longer OS across all lines of therapy, whereas a history of hepatitis C infection was associated with improved OS in patients treated with ICI in the 1st-line setting. This evidence concerns the gene ALB and hepatitis C virus infection.